We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+22.79%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$986M
AUM Growth
+$157M
Cap. Flow
+$52.5M
Cap. Flow %
5.32%
Top 10 Hldgs %
59.81%
Holding
50
New
8
Increased
8
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$82.5M
2
MRUS
Merus
MRUS
+$43.9M
3
XNCR icon
Xencor
XNCR
+$23.6M
4
RCUS icon
Arcus Biosciences
RCUS
+$21.2M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$14.1M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$58M
2
CTMX icon
CytomX Therapeutics
CTMX
+$23.7M
3
ANAB icon
AnaptysBio
ANAB
+$23.5M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$11.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 83.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCT
26
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$10.8M 1.1%
4,355
-3,555
-45% -$7.92M
FWP
27
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$10.3M 1.05%
679,302
+185,714
+38% +$4.52M
RGLS
28
DELISTED
Regulus Therapeutics
RGLS
$10M 1.02%
116,452
– –
VSTM icon
29
Verastem
VSTM
$510M
$8.16M 0.83%
228,083
+40,583
+22% +$1.57M
KDNY
30
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$7.5M 0.76%
+161,307
New +$5.9M
ALBO
31
DELISTED
Albireo Pharma Inc
ALBO
$7.33M 0.74%
+225,000
New +$7.58M
FBRX icon
32
Forte Biosciences
FBRX
$1.57B
$5.98M 0.61%
1,345
-139
-9% -$644K
CFRX
33
DELISTED
ContraFect Corporation
CFRX
$5.57M 0.56%
4,375
– –
MTEM
34
DELISTED
Molecular Templates, Inc.
MTEM
$5.51M 0.56%
45,909
-2,366
-5% -$356K
ALPN
35
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.41M 0.55%
675,759
– –
GNCA
36
DELISTED
Genocea Biosciences, Inc.
GNCA
$5.25M 0.53%
+625,000
New +$5.19M
VIRX
37
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.58M 0.46%
48,132
-10,245
-18% -$1.76M
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.06B
$3.53M 0.36%
720,830
-2,868,000
-80% -$10.6M
PTGX icon
39
Protagonist Therapeutics
PTGX
$8.79B
$3.48M 0.35%
405,600
+111,483
+38% +$2.1M
FRTX
40
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$2.04M 0.21%
4,474
– –
EPIX
41
DELISTED
ESSA Pharma
EPIX
$1.94M 0.2%
+509,182
New +$2.12M
LOXO
42
DELISTED
Loxo Oncology, Inc
LOXO
$506K 0.05%
4,386
– –
OREX
43
DELISTED
Orexigen Therapeutics, Inc.
OREX
$108K 0.01%
534,900
-200,076
-27% -$184K
CTMX icon
44
CytomX Therapeutics
CTMX
$675M
– –
-1,124,483
Closed -$23.7M
CBIO
45
Crescent Biopharma
CBIO
$535M
– –
-4,975
Closed -$8.35M
FLNA
46
Filana Therapeutics
FLNA
$48.8M
– –
-325,509
Closed -$1.3M
ITCI
47
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-273,350
Closed -$3.96M
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,608,433
Closed -$4.63M
ANTH
49
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-1,216,403
Closed -$2.01M
CASC
50
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-3,133,224
Closed -$11.6M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2018 Portfolio in Review

As of Q1 2018, BVF Inc held 50 positions worth $986M, up 19% from $830M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

BVF Inc deployed $52.5M of net new capital in Q1 2018, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Ironwood Pharmaceuticals: 6,617,626 shares worth $85.5M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $58M trimmed.

  • BVF Inc's largest Q1 2018 buy was Ironwood Pharmaceuticals: 6,617,626 shares worth $85.5M.
  • BVF Inc added most to Corvus Pharmaceuticals in Q1 2018, an estimated $14.1M increase.
  • BVF Inc's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $58M.
  • BVF Inc fully exited CytomX Therapeutics in Q1 2018, selling an estimated $23.7M.
  • BVF Inc's ten largest holdings make up 60% of its $986M portfolio in Q1 2018.
  • BVF Inc opened 8 new positions and closed 7 in Q1 2018.
  • BVF Inc's portfolio value rose 19% quarter-over-quarter to $986M.

Based on BVF Inc's 13F filing for Q1 2018, filed 7 May 2018.